10778 related articles for article (PubMed ID: 15693645)
1. Fluorodeoxyglucose-PET in the management of malignant melanoma.
Kumar R; Mavi A; Bural G; Alavi A
Radiol Clin North Am; 2005 Jan; 43(1):23-33. PubMed ID: 15693645
[TBL] [Abstract][Full Text] [Related]
2. Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma.
Kumar R; Alavi A
Curr Opin Oncol; 2005 Mar; 17(2):154-9. PubMed ID: 15725921
[TBL] [Abstract][Full Text] [Related]
3. Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node.
Wagner T; Meyer N; Zerdoud S; Julian A; Chevreau C; Payoux P; Courbon F
Br J Dermatol; 2011 Jun; 164(6):1235-40. PubMed ID: 21332457
[TBL] [Abstract][Full Text] [Related]
4. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy.
Wagner JD; Schauwecker D; Davidson D; Coleman JJ; Saxman S; Hutchins G; Love C; Hayes JT
J Clin Oncol; 1999 May; 17(5):1508-15. PubMed ID: 10334538
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of positron emission tomography for the detection of melanoma metastases.
Holder WD; White RL; Zuger JH; Easton EJ; Greene FL
Ann Surg; 1998 May; 227(5):764-9; discussion 769-71. PubMed ID: 9605668
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for lymphoscintigraphy and F18 FDG PET scans in melanoma.
Uren RF; Howman-Giles R; Chung D; Thompson JF
J Surg Oncol; 2011 Sep; 104(4):405-19. PubMed ID: 21858836
[TBL] [Abstract][Full Text] [Related]
8. Lack of clinical impact of
Liu J; Larcos G; Howle J; Veness M
Australas J Dermatol; 2017 May; 58(2):99-105. PubMed ID: 26459330
[TBL] [Abstract][Full Text] [Related]
9. Melanoma.
Bastiaannet E; Hoekstra HJ; Hoekstra OS
Methods Mol Biol; 2011; 727():123-39. PubMed ID: 21331932
[TBL] [Abstract][Full Text] [Related]
10. The value of lymph node ultrasound and whole body
Stahlie EHA; van der Hiel B; Bruining A; van de Wiel B; Schrage YM; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
Eur J Surg Oncol; 2021 May; 47(5):1157-1162. PubMed ID: 33353826
[TBL] [Abstract][Full Text] [Related]
11. Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT.
Akcali C; Zincirkeser S; Erbagcý Z; Akcali A; Halac M; Durak G; Sager S; Sahin E
J Int Med Res; 2007; 35(4):547-53. PubMed ID: 17697533
[TBL] [Abstract][Full Text] [Related]
12. [Role of FDG PET-CT in cutaneous melanoma].
Nicol I; Chuto G; Gaudy-Marqueste C; Brenot-Rossi I; Grob JJ; Richard MA
Bull Cancer; 2008 Nov; 95(11):1089-101. PubMed ID: 19036682
[TBL] [Abstract][Full Text] [Related]
13. Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?
Schaarschmidt BM; Grueneisen J; Stebner V; Klode J; Stoffels I; Umutlu L; Schadendorf D; Heusch P; Antoch G; Pöppel TD
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2093-2102. PubMed ID: 29876618
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.
Gellén E; Sántha O; Janka E; Juhász I; Péter Z; Erdei I; Lukács R; Fedinecz N; Galuska L; Remenyik É; Emri G
J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1938-44. PubMed ID: 25753249
[TBL] [Abstract][Full Text] [Related]
15. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma.
Clark PB; Soo V; Kraas J; Shen P; Levine EA
Arch Surg; 2006 Mar; 141(3):284-8. PubMed ID: 16549694
[TBL] [Abstract][Full Text] [Related]
16. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma.
Havenga K; Cobben DC; Oyen WJ; Nienhuijs S; Hoekstra HJ; Ruers TJ; Wobbes T
Eur J Surg Oncol; 2003 Oct; 29(8):662-4. PubMed ID: 14511614
[TBL] [Abstract][Full Text] [Related]
17. FDG PET in early stage cutaneous malignant melanoma.
McIvor J; Siew T; Campbell A; McCarthy M
J Med Imaging Radiat Oncol; 2014 Apr; 58(2):149-54; quiz 266. PubMed ID: 24690243
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
[TBL] [Abstract][Full Text] [Related]
19. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis.
Rodriguez Rivera AM; Alabbas H; Ramjaun A; Meguerditchian AN
Surg Oncol; 2014 Mar; 23(1):11-6. PubMed ID: 24556310
[TBL] [Abstract][Full Text] [Related]
20. The utility of PET-CT in the staging and management of advanced and recurrent malignant melanoma.
Twycross SH; Burger H; Holness J
S Afr J Surg; 2019 Sep; 57(3):44-49. PubMed ID: 31392864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
